0001567619-22-021928.txt : 20221221 0001567619-22-021928.hdr.sgml : 20221221 20221221160722 ACCESSION NUMBER: 0001567619-22-021928 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221219 FILED AS OF DATE: 20221221 DATE AS OF CHANGE: 20221221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wang Xiaolin CENTRAL INDEX KEY: 0001849181 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39219 FILM NUMBER: 221478536 MAIL ADDRESS: STREET 1: C/O REVOLUTION MEDICINES, INC. STREET 2: 700 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc1.xml FORM 4 X0306 4 2022-12-19 0 0001628171 Revolution Medicines, Inc. RVMD 0001849181 Wang Xiaolin C/O REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY CA 94063 0 1 0 0 See Remarks Common Stock 2022-12-19 4 S 0 708 22.9398 D 30527 D Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. This transaction was executed in multiple trades in prices ranging from $22.4706 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 22,550 RSUs. EVP, Clinical Development /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang 2022-12-21